INCRET

Linagliptin 2.5 and 5mg tab

Indication

Indicated to treat type 2 diabetes

Mode of Action

Inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP. Both incretin hormones are involved in the physiological regulation of the glucose homeostasis. Inhibition of DPP4 leads to increased and prolonged active incretin levels.

Pharmacokinetics

Half-life is 12 hrs with bioavailability 30%. 90% of the dose is excreted unchanged and eliminated via enterohepatic circulation.

Dosage and Recommendation

5mg once daily is recommended. It can be taken irrespective of food intake.

Packing and Presentation

Each strip of Incret contains 10 tablets in a box of 10 x 10s.